King for a Day? On What’s Wrong With Changing the World for the Better
By Roland Nadler,
Law and Biosciences Blog
| 01. 04. 2016
Untitled Document
Philosopher Russell Blackford argues that regulatory authorities should not allow “the tyranny of mere public opinion” to impede technological advances in genomics. I disagree strenuously. To explain why, let’s talk for a minute about … Mark Zuckerberg.
It was perhaps the last big Silicon Valley news story of 2015: Facebook’s CEO blew the headlines wide open when he and Dr. Priscilla Chan announced that they will dedicate 99% of their Facebook shares to their eponymous charitable LLC within their lifetimes. Widespread adulation was the order of the day.
You don’t have to be Gawker gadfly Sam Biddle to find some cause for concern, though. Two unelected, unaccountable magnates now wield a $45 billion policymaking LLC, unimpeded by the usual tax-law strictures for charitable organizations. They can and will remake swaths of the world as they see fit. What’s your recourse if you disagree with their definition of “better”? (Think you’ll never disagree? I’ve got some New Jersey charter schools to sell you.)
So, why rehearse the well-worn debate over philanthropy’s democratic legitimacy on a law and biosciences blog? Money isn’t the only way to change the world. Teams...
Related Articles
Cathy Tie seems to be good at starting businesses but not so dedicated to maintaining them. CGS, like many others, first heard of her thanks to Caiwei Chen and Antonio Regalado in MIT Technology Review, May 2025, as the partner (perhaps bride) of the notorious Chinese scientist He Jiankui, described in the headline as “China’s Frankenstein.” He prefers “Chinese Darwin.” She ran his Twitter account for a while, contributing such gems as:
Get in luddite, we’re going gene editing...
By Laura DeFrancesco, Nature Biotechnology | 03.17.2026
The first gene editors designed to fix genetic lesions in mutation-agnostic ways are poised to enter the clinic. Tessera Therapeutics and Alltrna, two Flagship Pioneering-funded companies, are gearing up to test novel genetic medicines in humans. Tessera received regulatory clearance...
By Darren Incorvaia, Fierce Biotech | 03.11.2026
A new method for safely inserting large chunks of DNA into genomes has now measured up in mice, potentially paving the way for the next generation of gene editing medicines.
The approach, which is described in a Nature paper...
By Carolyn Riley Chapman and Nirvan Bhatia, Hastings Bioethics Forum | 03.12.2026
Last year, researchers saved an infant named KJ from a life-threatening rare metabolic disorder using a customized gene editing therapy. This was the first time that an individualized gene therapy was used to treat a human patient, and it has...